Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CytomX Therapeutics (CTMX) Return on Capital Employed (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Return on Capital Employed for 11 consecutive years, with 0.19% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Capital Employed fell 4.0% year-over-year to 0.19%, compared with a TTM value of 0.19% through Sep 2025, down 4.0%, and an annual FY2024 reading of 0.33%, up 42.0% over the prior year.
  • Return on Capital Employed was 0.19% for Q3 2025 at CytomX Therapeutics, down from 0.44% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.61% in Q1 2025 and bottomed at 1.11% in Q4 2022.
  • Average Return on Capital Employed over 5 years is 0.15%, with a median of 0.22% recorded in 2021.
  • The sharpest move saw Return on Capital Employed crashed -90bps in 2022, then soared 100bps in 2023.
  • Year by year, Return on Capital Employed stood at 0.22% in 2021, then tumbled by -413bps to 1.11% in 2022, then soared by 90bps to 0.12% in 2023, then surged by 587bps to 0.57% in 2024, then tumbled by -67bps to 0.19% in 2025.
  • Business Quant data shows Return on Capital Employed for CTMX at 0.19% in Q3 2025, 0.44% in Q2 2025, and 0.61% in Q1 2025.